Asha Therapeutics is looking to test the therapeutic activity of their novel SARM1 inhibitor as a potential treatment option for CMT2A. CMT2A is caused by mutations in the MFN2 gene, leading to mitochondrial dysfunction and nerve degeneration. Prior studies have shown that genetic removal of SARM1, a key driver in nerve degeneration, prevents disease in CMT2A animals. Dr. Bradlee Heckmann, PhD, will walk us through Asha’s approach and the status of the project funded by CMTRF in early 2025.

Date: November 6, 2025
Time: 7:00 p.m. ET
Location: Zoom

There is no cost to attend. To register, click here.

The Story and The Science Behind Augustine Therapeutics’ $85M Raise

In 2023, CMTRF invested $683,000 in Augustine Therapeutics to support their groundbreaking work on a small-molecule HDAC6 inhibitor for CMT. That investment became the foundation for something extraordinary — Augustine leveraged those initial funds to advance and optimize their lead drug candidate, AGT-100216, and attract additional funding of $85 million. This funding will be used to advance their CMT drug candidate through clinical trials, marking a major milestone in CMT research.

In this exclusive webinar, Augustine Therapeutics’ CEO, Gerhard Koenig, Ph.D., and advisor, Dr. Andy Hu, along with the team from CMTRF, discussed how this remarkable fundraising success happened, the science behind their promising HDAC6 inhibitor, and what this breakthrough means for the future of CMT treatments.